Tuesday 16 August 2022 - 02:14
In Business 42 Years - Since 1980
PLEASE NOTE: During August 2022 we are doing a comprehensive revision of our customer service workflow. This includes training of current and new personnel. We are expecting that these changes will have only very minimal effects on our overall order processing and shipping activities. However, we do ask any customers who prefer that their shipments go out on Fridays to contact our Customer Service group and let them know about your preferences in advance. Thank you.
Reminder: Genuine LC Laboratories® brand PMA, which we have been manufacturing in the U.S. for more
than 40 years, is available directly from us: Cat No. P-1680 Phorbol 12-Myristate 13-Acetate, >99.5%.
Our PMA is also available from our >50 U.S. and international distributors, and from more than a dozen
major biochemical reagent "resellers" (who sell our PMA under their own brand names and labels)
FREE SHIPPING TO THE U.S. AND 32 OTHER COUNTRIES! [Read more].
N-5665 Niraparib, Free Base, >99%
Synonyms : [MK-4827]
Related Terms : [Zejula]
- Size
- US $
- €
- £
- ¥
- 5 mg
- 42
- 41
- 34
- 5,600
- In stock
- 10 mg
- 56
- 54
- 46
- 7,400
- In stock
- 25 mg
- 75
- 73
- 62
- 10,000
- In stock
- 50 mg
- 96
- 94
- 79
- 12,700
- In stock
- 100 mg
- 143
- 140
- 118
- 19,000
- In stock
- 200 mg
- 242
- 237
- 200
- 32,100
- In stock
- 500 mg
- 477
- 467
- 394
- 63,300
- In stock
- 1 g
- 695
- 681
- 574
- 92,200
- In stock
- 2 g
- 1,130
- 1,107
- 934
- 149,900
- In stock
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
- M.W. 320.39
- C19H20N4O
- [1038915-60-4]
Solubility: DMSO.
- Niraparib, also known as MK-4827, is a poly(ADP-ribose)polymerase (PARP) inhibitor. Niraparib displayed excellent PARP 1 and 2 inhibition with IC50 values of 3.8 and 2.1 nM, respectively, and in a whole cell assay, it inhibited PARP activity with an IC50 of 4 nM, and inhibited proliferation of cancer cells with mutant BRCA-1 and BRCA-2, with IC50 values of 10-100 nM. Niraparib was well tolerated in vivo and showed antitumor activity as a single agent in a xenograft model of BRCA-1 deficient cancer. Jones P., et al. "Discovery of 2-{4-[(3S)-piperidin-3-yl]phenyl}-2H-indazole-7-carboxamide (MK-4827): a novel oral poly(ADP-ribose)polymerase (PARP) inhibitor efficacious in BRCA-1 and -2 mutant tumors." J. Med. Chem. 52: 7170-7185 (2009).
- Niraparib enhanced radiation-induced cytotoxicity in neuroblastoma cells. In vivo treatment with niraparib and radiation prolonged survival of mice in a murine xenograft model of metastatic neuroblastoma when compared to single modalities. Mueller S., et al. "Poly (ADP-Ribose) polymerase inhibitor MK-4827 together with radiation as a novel therapy for metastatic neuroblastoma." Anticancer Res. 33: 755-762 (2013).
- A phase 1 clinical trial demonstrated niraparib inhibited PARP more than 50% at doses greater than 80 mg/day and had antitumour activity at doses beyond 60 mg/day. Antitumour activity of niraparib was reported in BRCA1 or BRCA2 mutation carriers with ovarian cancer, breast cancer, and in patients with sporadic high-grade serous ovarian cancer, non-small-cell lung cancer, and prostate cancer. Sandhu S.K., et al. "The poly(ADP-ribose) polymerase inhibitor niraparib (MK4827) in BRCA mutation carriers and patients with sporadic cancer: a phase 1 dose-escalation trial." Lancet Oncol. 14: 882-892 (2013).
- Related CAS numbers: 1038915-64-8 for the hydrochloride salt; 1038915-73-9 for the methanesulfonate salt; 1171196-88-5 for the sulfate salt.
- Niraparib (as the Tosylate monohydrate) is the active ingredient in the drug sold under the trade name Zejula®. This drug has been approved in at least one country for use in adult patients with recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer who are in a complete or partial response to platinum-based chemotherapy. NOTE: THE NIRAPARIB SOLD BY THE LC LABORATORIES IS NOT ZEJULA®, AND IS NOT FOR HUMAN USE.
- Sold for laboratory or manufacturing purposes only; not for human, veterinary, food, or household use.
- This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
- Not available in some countries; not available to some institutions; not available for some uses.
